G
Gordon D.O. Lowe
Researcher at University of Glasgow
Publications - 564
Citations - 47429
Gordon D.O. Lowe is an academic researcher from University of Glasgow. The author has contributed to research in topics: Risk factor & Population. The author has an hindex of 105, co-authored 560 publications receiving 44327 citations. Previous affiliations of Gordon D.O. Lowe include Robertson Centre for Biostatistics & University of Aberdeen.
Papers
More filters
Journal ArticleDOI
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
John Danesh,J. G. Wheeler,Gideon M. Hirschfield,Shinichi Eda,Gudny Eiriksdottir,Ann Rumley,Gordon D.O. Lowe,Mark B. Pepys,Vilmundur Gudnason +8 more
TL;DR: The long-term stability of C-reactive protein values was similar to that of both blood pressure and total serum cholesterol, and recommendations regarding its use in predicting the likelihood of coronary heart disease may need to be reviewed.
Journal ArticleDOI
C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Stephen Kaptoge,E Di Angelantonio,Gordon D.O. Lowe,Mark B. Pepys,Simon G. Thompson,Rory Collins,John Danesh +6 more
TL;DR: CRP concentration has continuous associations with the risk of coronary heart disease, ischaemic stroke, vascular mortality, and death from several cancers and lung disease that are each of broadly similar size.
Journal ArticleDOI
C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction
Stephen Kaptoge,Emanuele Di Angelantonio,Lisa Pennells,Angela M. Wood,Ian R. White,Pei Gao,Matthew G. Walker,Alexander M. W. Cargill Thompson,Nadeem Sarwar,Muriel J. Caslake,Adam S. Butterworth,Philippe Amouyel,Gerd Assmann,Stephan J. L. Bakker,Elizabeth L M Barr,Elizabeth Barrett-Connor,Emelia J. Benjamin,Cecilia Björkelund,Hermann Brenner,Eric J. Brunner,Robert Clarke,Jackie A. Cooper,Peter Cremer,Mary Cushman,Gilles R. Dagenais,Ralph B. D'Agostino,Rachel Dankner,George Davey-Smith,Dorly J. H. Deeg,Jacqueline M. Dekker,Gunnar Engström,Aaron R. Folsom,F. Gerry R. Fowkes,John Gallacher,J. Michael Gaziano,Simona Giampaoli,Richard F. Gillum,Albert Hofman,Barbara V. Howard,Erik Ingelsson,Hiroyasu Iso,Torben Jørgensen,Stefan Kiechl,Akihiko Kitamura,Yutaka Kiyohara,Wolfgang Koenig,Daan Kromhout,Lewis H. Kuller,Debbie A Lawlor,Tom W. Meade,Aulikki Nissinen,Børge G. Nordestgaard,Altan Onat,Demosthenes B. Panagiotakos,Bruce M. Psaty,Beatriz L. Rodriguez,Annika Rosengren,Veikko Salomaa,Jussi Kauhanen,Jukka T. Salonen,Jonathan A. Shaffer,Steven Shea,Ian Ford,Coen D.A. Stehouwer,Timo E. Strandberg,Robert W. Tipping,Alberto Tosetto,Sylvia Wassertheil-Smoller,Patrik Wennberg,Rudi G. J. Westendorp,Peter H. Whincup,Lars Wilhelmsen,Mark Woodward,Gordon D.O. Lowe,Nicholas J. Wareham,Kay-Tee Khaw,Naveed Sattar,Chris J. Packard,Vilmundur Gudnason,Paul M. Ridker,Mark B. Pepys,Simon G. Thompson,John Danesh +82 more
TL;DR: It is estimated that under current treatment guidelines, assessment of the CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened.
Journal ArticleDOI
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I. Swerdlow,Michael V. Holmes,Karoline Kuchenbaecker,Engmann Jel.,Tina Shah,Reecha Sofat,Yiran Guo,C Chung,Anne Peasey,Roman Pfister,Simon P. Mooijaart,Helen Ireland,Maarten Leusink,Claudia Langenberg,KaWah Li,Jutta Palmen,Phil Howard,Jackie A. Cooper,Fotios Drenos,John Hardy,Mike A. Nalls,Yun Li,Gordon D.O. Lowe,Marlene C. W. Stewart,S. J. Bielinski,Julian Peto,Nicholas J. Timpson,John Gallacher,Malcolm G. Dunlop,Richard S. Houlston,Ian Tomlinson,Ioanna Tzoulaki,Jian'an Luan,Boer Jma.,Nita G. Forouhi,N. C. Onland-Moret,Y. T. van der Schouw,Renate B. Schnabel,Jaroslav A. Hubacek,Růžena Kubínová,Migle Baceviciene,Abdonas Tamosiunas,Andrzej Pajak,Roman Topor-Madry,Sofia Malyutina,Damiano Baldassarre,Bengt Sennblad,Elena Tremoli,U de Faire,Luigi Ferrucci,S Bandenelli,Tetsu Tanaka,James F. Meschia,AB Singleton,Gerjan Navis,I. Mateo Leach,Bakker Sjl.,Ron T. Gansevoort,Ian Ford,Stephen E. Epstein,Mary-Susan Burnett,Joe Devaney,Johan Wouter Jukema,Westendorp Rgj.,G Jan de Borst,Y. van der Graaf,P A de Jong,Mailand-van der Zee A-H.,Olaf H. Klungel,A. de Boer,P. A. Doevendans,Jeffrey W. Stephens,Charles B. Eaton,Jennifer G. Robinson,JoAnn E. Manson,F G Fowkes,Timothy M. Frayling,Jenna Price,Peter H. Whincup,Richard W Morris,Debbie A Lawlor,George Davey Smith,Yoav Ben-Shlomo,Susan Redline,Leslie A. Lange,Meena Kumari,Nicholas J. Wareham,Verschuren Wmm.,Emelia J. Benjamin,John C. Whittaker,Anders Hamsten,Frank Dudbridge,Delaney Jac.,Andrew Wong,Diana Kuh,Rebecca Hardy,Berta Almoguera Castillo,John Connolly,P. van der Harst,Eric J. Brunner,Michael Marmot,Christina L. Wassel,Steve E. Humphries,P.J. Talmud,Mika Kivimäki,Folkert W. Asselbergs,Mikhail I. Voevoda,Martin Bobak,Hynek Pikhart,James G. Wilson,Hakon Hakonarson,Alexander P. Reiner,Brendan J. Keating,Naveed Sattar,Aroon D. Hingorani,Juan P. Casas +115 more
TL;DR: IL6R blockade could provide a novel therapeutic approach to prevention of coronary heart disease that warrants testing in suitably powered randomised trials and could help to validate and prioritise novel drug targets or to repurpose existing agents and targets for new therapeutic uses.
Journal ArticleDOI
Lipoprotein-Associated Phospholipase A2 as an Independent Predictor of Coronary Heart Disease
Christopher J. Packard,Denis St. J. O’Reilly,Muriel J. Caslake,Alex D. McMahon,Ian Ford,Josephine Cooney,Colin H. Macphee,Keith E. Suckling,Mala Krishna,Francis E. Wilkinson,Ann Rumley,Gordon D.O. Lowe +11 more
TL;DR: Elevated levels of lipoprotein-associated phospholipase A2 appear to be a strong risk factor for coronary heart disease, a finding that has implications for atherogenesis and the assessment of risk.